Dr. Hideaki Miyake

Dr. Hideaki Miyake

M.D. Kobe University (Kobe, Japan), 1993 
Ph.D. Kobe University (Kobe, Japan), 1998 
Postdoctoral fellowship, Vancouver Prostate Centre (Vancouver, Canada), 1998-2000

Associate Members

Associate Professor, Division of Urology, Kobe University Graduate School of Medicine (Kobe, Japan)
Active Staff, Kobe University Hospital (Kobe, Japan)


After graduating from Kobe University Graduate school of Medicine, Dr. Miyake joined the Vancouver Prostate Centre as a postdoctoral fellow in 1998. He worked with Dr. Martin Gleave investigating the molecular mechanisms involved in the progression of prostate cancer to androgen-independence and the development of a novel therapeutic strategy targeted against antiapoptotic genes using antisense oligonucleotide technology. To date, he has published more than 300 peer-reviewed papers, including 46 under joint authorship with Dr. Gleave. He is a recipient of many awards, such as the First prize in the Essay Contest at the CUA annual meeting in 1999, First prize in the Essay Contest at the AUA annual meeting in 2000 and Best Paper Award of the Clinical Section at the JUA annual meeting in 2008.

Dr. Miyake’s current research focuses on a wide range of topics associated with urological oncology, including the role of inflammatory cytokines as activators of androgen receptor, the impact of the prostate's microenvironment on local aggressiveness of prostate cancer and the overcoming of acquired resistance of renal cancer to molecular targeted agents. Moreover, he has tried to develop novel therapies for urological cancers by combining conventional therapeutic modalities and OGX-011, an antisense oligonucleotide inactivating the cytoprotective chaperon clusterin, in collaboration with Dr. Gleave.

Dr. Miyake is currently playing a central role in the Division of Urology, Kobe University Hospital as a clinical scientist and urologic surgeon. Therefore, he is also performing a number of clinical studies focusing on a wide variety of interesting topics, such as the development of extended radical prostatectomy for locally advanced prostate cancer, the improvement of functional outcomes in bladder cancer patients with orthotopic neobladder and the assessment of useful sequential therapy for metastatic renal cancer using molecular targeted agents. In addition, as the Chair of the Urological Oncology Group at Kobe University Hospital, he provides access for patients with urological cancer to the latest clinical trials using novel drugs.

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.


2016 Step Up team

Step Up Challenge fundraiser: February 25, 2018

The annual Step Up Challenge, raising funds for Prostate Cancer Canada, takes place in Vancouver on Sunday February 25. Click here to sponsor our relay team as they climbs 379 floors. Click here to volunteer to help with the event.

It's a Snow Day poster

It's A Snow Day at Mt. Seymour: March 9

Mt. Seymour is hosting It's A Snow Day, a fundraiser for Prostate Cancer Foundation BC, on Friday March 9. The event will include slope time, a reception, and a silent auction. Click here for more details including how to register, donate and/or sponsor.




Work at the Vancouver Prostate Centre

Thursday, January 18, 2018

Discovery of a promising new medication to block "master key" of cancer growth

Dr. Chris Ong
Tuesday, February 20, 2018

Drs. Wyatt and Chi: ctDNA predicts resistance to AR-targeted therapy

VCHRI News article on study of ctDNA predicting resistance to AR-targeted therapy

Make A Difference

Help the Vancouver Prostate Centre fund research to find better treatments and a cure.